Alpha 2.0
Login Register
» Authors » Glenn Pixton

Glenn Pixton

Explore the profile of Glenn Pixton including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 139
Followers 0
Related Specialties
Rheumatology
General Medicine
Neurology
Top 10 Co-Authors
Mark T Brown
Christine R West
Lars Viktrup
Thomas J Schnitzer
Almasa Bass
Gernot Wolfram
Kenneth M Verburg
Isabelle Davignon
Jacquelyn G Wilson
Richard L Rauck
Published In
Phys Sportsmed
Health Qual Life Outcomes
Semin Arthritis Rheum
Arthritis Res Ther
Pain
Affiliations
Soon will be listed here.
Recent Articles
1.
Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics
Fullerton T, Pixton G
J Pain Res . 2024 May; 17:1751-1760. PMID: 38764606
Purpose: To examine use of concomitant analgesics and antiemetics during treatment with rimegepant in adults with migraine. Patients And Methods: This was a post hoc analysis of a long-term, open-label,...
2.
Efficacy, General Safety, and Joint Safety of Tanezumab in Japanese Patients with Osteoarthritis: Subgroup Analyses from Two Randomized, Phase 3 Studies
Miki K, Ohta M, Abe M, Yoshimatsu H, Fujii K, Ebata N, et al.
Pain Ther . 2022 May; 11(3):827-844. PMID: 35538185
Introduction: Tanezumab is a monoclonal antibody against nerve growth factor that is under investigation for the treatment of osteoarthritis (OA) pain. We conducted subgroup analyses of two randomized phase 3...
3.
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study
Neogi T, Hunter D, Churchill M, Shirinsky I, White A, Guermazi A, et al.
Arthritis Res Ther . 2022 Mar; 24(1):78. PMID: 35351194
Background: A recent phase 3 study demonstrated that treatment with tanezumab, a nerve growth factor inhibitor, or nonsteroidal anti-inflammatory drugs (NSAIDs) improves pain and physical function in participants with moderate-to-severe...
4.
General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials
Berenbaum F, Schnitzer T, Kivitz A, Viktrup L, Hickman A, Pixton G, et al.
Arthritis Care Res (Hoboken) . 2021 May; 74(6):918-928. PMID: 33973384
Objective: This pooled analysis of 3 randomized, placebo-controlled trials (16-24 week treatment and 8-24 week follow-up) assessed safety of subcutaneous tanezumab (2.5-10 mg every 8 weeks) in 1,840 patients with...
5.
Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial
Hochberg M, Carrino J, Schnitzer T, Guermazi A, Walsh D, White A, et al.
Arthritis Rheumatol . 2021 Feb; 73(7):1167-1177. PMID: 33538113
Objective: To assess the long-term safety and 16-week efficacy of subcutaneous tanezumab in patients with hip or knee osteoarthritis (OA). Methods: This was a phase III randomized, double-blind, active treatment-controlled...
6.
Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study
Schnitzer T, Khan A, Bessette L, Davignon I, Brown M, Pixton G, et al.
Semin Arthritis Rheum . 2020 Apr; 50(3):387-393. PMID: 32252976
Objective: To examine the onset and maintenance of efficacy of subcutaneous tanezumab for pain relief and functional improvement in difficult-to-treat patients with moderate-to-severe osteoarthritis (OA) in a 16-week dose-titration study...
7.
Effects of naltrexone exposure observed in two phase three studies with ALO-02, an extended-release oxycodone surrounding sequestered naltrexone
Gimbel J, Rauck R, Bass A, Wilson J, Pixton G, Malhotra B, et al.
J Opioid Manag . 2019 Dec; 15(5):417-427. PMID: 31849032
Objective: To evaluate the clinical effects of naltrexone following ALO-02 administration. Design: Two phase three studies: an open-label, single-arm safety study, and a double-blind, placebo-controlled, randomized withdrawal, efficacy study (ClinicalTrials.gov...
8.
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial
Schnitzer T, Easton R, Pang S, Levinson D, Pixton G, Viktrup L, et al.
JAMA . 2019 Jul; 322(1):37-48. PMID: 31265100
Importance: Patients with osteoarthritis (OA) may remain symptomatic with traditional OA treatments. Objective: To assess 2 subcutaneous tanezumab dosing regimens for OA. Design, Setting, And Participants: A randomized, double-blind, multicenter...
9.
Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain
Weil A, Masters E, Barsdorf A, Bass A, Pixton G, Wilson J, et al.
Health Qual Life Outcomes . 2017 Oct; 15(1):202. PMID: 29041942
Background: The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone, in the treatment of chronic low back pain (CLBP) was studied in a 12-week randomized controlled...
10.
Measurement of Drug Liking in Abuse Potential Studies: A Comparison of Unipolar and Bipolar Visual Analog Scales
Setnik B, Roland C, Pixton G, Webster L
J Clin Pharmacol . 2016 Jul; 57(2):266-274. PMID: 27444046
Abuse liability studies usually measure drug liking using 100-mm visual analog scales (VAS), presented as unipolar (liking measured on entire scale) or bipolar (liking and disliking measured with a neutral...